Published in Pharma Law Weekly, June 1st, 2004
Excluding certain non-cash charges, the non-GAAP net loss in the first quarter of 2004 would have been $12.0 million, or $0.13 per basic and diluted share.
On March 31, 2004, PDL had cash, cash equivalents, marketable securities and restricted investments totaling approximately $466.9 million, compared with $505.0 million at December 31, 2003.
The March 31, 2004...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.